A groundbreaking clinical trial has unveiled a new daily pill that could revolutionise weight-loss treatment for individuals with type 2 diabetes, potentially offering a more effective oral alternative to existing GLP-1 medications like Wegovy and Mounjaro.
Orforglipron: A Promising Oral Contender
The drug, known as orforglipron and developed by pharmaceutical giant Eli Lilly, targets the same GLP-1 receptors as oral semaglutide. It functions by lowering blood sugar levels, slowing digestion, and suppressing appetite. Notably, unlike semaglutide tablets, orforglipron does not require administration on an empty stomach, enhancing its convenience for patients.
Currently, orforglipron has not received regulatory approval in the UK, US, or Europe, though the US Food and Drug Administration is actively reviewing it. At present, semaglutide remains the sole GLP-1 medication available in pill form for type 2 diabetes in the US, marketed under the name Rybelsus.
Trial Results: Superior Weight Loss and Efficacy
The first phase 3 trial, named Achieve-3 and funded by Eli Lilly, involved over 1,500 adults with type 2 diabetes from 131 medical research centres and hospitals across Argentina, China, Japan, Mexico, and the US. Participants were administered either 12mg or 36mg of orforglipron, or 7mg or 14mg of oral semaglutide, over a one-year period.
The findings were striking: patients taking orforglipron experienced an average weight loss of 6-8% of their body weight, compared to 4-5% for those on semaglutide. Additionally, participants on orforglipron recorded lower average blood sugar levels at the trial's conclusion than those on semaglutide.
Expert Insights and Considerations
Tam Fry, chair of the National Obesity Forum, highlighted the potential of orforglipron, stating, "Orforglipron could prove itself as the treatment of choice for the very obese diabetic. Its real bonus is in its straightforward use." However, he cautioned that its availability must be more strictly controlled than semaglutide to prevent similar life-threatening misuse.
Dr Marie Spreckley from the MRC epidemiology unit at the University of Cambridge noted, "Higher discontinuation due to adverse events, particularly gastrointestinal symptoms, is a key consideration and may have implications for tolerability and adherence in real-world settings." The trial reported that 9-10% of orforglipron participants stopped treatment due to side-effects, primarily gastrointestinal issues, compared to 4-5% in the semaglutide groups.
Professor Naveed Sattar of the University of Glasgow emphasised the importance of these findings, saying, "The more effective oral medicines we have to help people with type 2 diabetes lose weight and keep it off, the better." He added that holistic approaches targeting weight, blood sugar, and cardiovascular risk simultaneously are likely to yield the greatest benefits, with incretin-based therapies potentially becoming first-line treatments within the next decade.
Despite the promising results, experts point out that longer-term safety, cardiovascular outcomes, and sustained effectiveness remain critical unanswered questions, as the trial lasted only one year. As research continues, orforglipron could pave the way for transformative, accessible weight-loss solutions for millions worldwide.
